Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

February 29, 2012

Conditions
Multiple Myeloma
Interventions
DRUG

CCI-779

Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles

DRUG

Bortezomib

Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles

Trial Locations (3)

48109

University of Michigan, Ann Arbor

63110

Washington University in Saint Louis, St Louis

02215

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER